On September 4, due to Shandong Branden Medical Devices Co., Ltd.(hereinafter referred to as “Branden”)and its sponsor withdrew the application for issuance and listing, and the Shanghai Stock Exchange terminated the review of its issuance and listing.On October 19, 2022, Branden’s application for an initial public offering (IPO) on the STAR Market was accepted by the Shanghai Stock Exchange.The planned fundraising amount is RMB 760 million, with no more than 20.52 million shares to be issued.The prospectus shows that Branden is a company that applies medical material modification technology to implantable and interventional medical devices. The company's main products include peripherally inserted central catheters (PICC), cranial external drainage systems, surgical drainage systems, and other medical consumables.From 2019 to 2021 and during the period from January to June 2022 (hereinafter referred to as the “Reporting Period”), Branden achieved operating revenues of RMB 177 million, RMB 237 million, RMB 210 million, and RMB 100 million, respectively, and net profits of RMB 31.3172 million, RMB 41.5551 million, RMB 42.8973 million, and RMB 18.4578 million, respectively, during the same periods.Pharmaceutical ResearchReportSharing CampCollection and Sharing of Mainstream Pharmaceutical Research Reports Across the Market
Only 0.8 yuan per day
EnjoyOver 1,800 articlesSelected Pharmaceutical Research Reports
New Additions in the Coming YearAdditional 500 articles
